REYON Pharmaceutical Co., Ltd. (KRX: 102460)

Market Cap	257.87B
Revenue (ttm)	148.99B
Net Income (ttm)	-104.46M
Shares Out	18.34M
EPS (ttm)	-6.00
PE Ratio	n/a
Forward PE	n/a
Dividend	150.00 (1.02%)
Ex-Dividend Date	n/a

Volume	27,559
Open	14,170
Previous Close	14,240
Day's Range	14,040 - 14,800
52-Week Range	11,170 - 18,650
Beta	1.00
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 14, 2024

About REYON Pharmaceutical

REYON Pharmaceutical Co., Ltd. manufactures and sells medicines. The company offers its products under the areas of adrenal corticosteroides; angiotensin II receptor antagonists; antibiotics; anticholinergics; antiemetic; antihypertensives; anti-inflammatory enzymes; antilipidemic, antirheumatic, and oral hypoglycemic agents; anti-peptic ulcer; antispasmodics; benign prostatic hypertrophy; cough and cold remedies; cardiac stimulant; genitourinary smooth muscle relaxants; hemostatics; immunosuppressants; rheumatoid arthritis; local anesthetics; ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1955
• Employees: 467
• Stock Exchange: Korea Stock Exchange
• Ticker Symbol: 102460

Financial Performance

In 2023, REYON Pharmaceutical's revenue was 151.07 billion, a decrease of -1.93% compared to the previous year's 154.04 billion. Earnings were 3.58 billion, a decrease of -51.30%.